Legend Biotech annual r&d spending
2018
2019
2020
2021
2022
2023
2024
2025
Legend Biotech R&D Spending Growth & History (LEGN)
Legend Biotech's r&d spending was $414.7M for fiscal 2025.
View full Legend Biotech company overviewLegend Biotech annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $414.7M | $1.2M | +0.29% |
| 2024 | 2024-12-31 | $413.5M | $31.3M | +8.19% |
| 2023 | 2023-12-31 | $382.2M | $46.6M | +13.87% |
| 2022 | 2022-12-31 | $335.6M | $22.3M | +7.12% |
| 2021 | 2021-12-31 | $313.3M | $81.2M | +34.97% |
| 2020 | 2020-12-31 | $232.2M | $70.2M | +43.36% |
| 2019 | 2019-12-31 | $161.9M | $101.3M | +167.07% |
| 2018 | 2018-12-31 | $60.6M | — | — |
Legend Biotech quarterly r&d spending
Q3.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $96.0M | −$2.3M | −2.34% |
| Q1 2026 | 2026-03-31 | $85.7M | −$16.2M | −15.92% |
| Q4 2025 | 2025-12-31 | $101.3M | −$3.1M | −2.93% |
| Q3 2025 | 2025-09-30 | $113.1M | $17.6M | +18.45% |
| Q2 2025 | 2025-06-30 | $98.3M | −$14.3M | −12.72% |
| Q1 2025 | 2025-03-31 | $101.9M | $960,000 | +0.95% |
| Q4 2024 | 2024-12-31 | $104.4M | −$1.3M | −1.21% |
| Q3 2024 | 2024-09-30 | $95.5M | −$333,000 | −0.35% |
| Q2 2024 | 2024-06-30 | $112.6M | $16.8M | +17.57% |
| Q1 2024 | 2024-03-31 | $101.0M | $16.1M | +18.94% |
| Q4 2023 | 2023-12-31 | $105.7M | — | — |
| Q3 2023 | 2023-09-30 | $95.9M | −$8.7M | −8.29% |
| Q2 2023 | 2023-06-30 | $95.8M | — | — |
| Q1 2023 | 2023-03-31 | $84.9M | — | — |
| Q3 2022 | 2022-09-30 | $104.5M | — | — |
Legend Biotech r&d spending trends
Over the last five fiscal years, Legend Biotech's r&d spending increased from $232.2M to $414.7M, a change of $182.5M. The latest reported quarter, Q2 2026, shows $96.0M.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Legend Biotech source filings ↗